Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a...

|By:, SA News Editor

Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial of European coverage for Esbriet and a subsequent delay in the commercialization.